Rein Therapeutics Inc. (RNTX) is a publicly traded company in the Healthcare sector, operating within the Medical - Pharmaceuticals industry. The company is headquartered in Austin, TX, United States. The current CEO is James Brian Windsor.
RNTX has IPO date of 2017-06-29, 11 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $45.7M.
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
